Abstract
Baricitinib, an oral, selective, and reversible Janus kinase 1/2 inhibitor, has been used for moderate-to-severe AD in patients aged >15 years in Japan from December 2020. In this study, we analyzed 14 Japanese adult patients with moderate-to-severe atopic dermatitis who were treated with baricitinib at Gunma University Hospital. We present our real-world data in combination with hematological data and improvement rates, and the relationship between serum interleukin-22 levels and disease activity of atopic dermatitis.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
